Matthew Rabinowitz (@MattRVerse) header
Matthew Rabinowitz (@MattRVerse) profile picture

Biotech, Healthcare, AI, Security, Founder & investor @NateraGenetics, @MyOmeinc, @NatureEye, Medici Therapeutics | R&D Leader of the Year 2024

Joined April 2022
Photo by Matthew Rabinowitz (@MattRVerse)Photo by Matthew Rabinowitz (@MattRVerse)Photo by Matthew Rabinowitz (@MattRVerse)Photo by Matthew Rabinowitz (@MattRVerse)Photo by Matthew Rabinowitz (@MattRVerse)Photo by Matthew Rabinowitz (@MattRVerse)Photo by Matthew Rabinowitz (@MattRVerse)Photo by Matthew Rabinowitz (@MattRVerse)Photo by Matthew Rabinowitz (@MattRVerse)Photo by Matthew Rabinowitz (@MattRVerse)
This week marks an important moment for Natera. I founded the company with a simple belief: every family deserves access to technologies that offer early detection of disease. Roughly twenty years later, I’m incredibly proud of what this company has become. I want to thank Steve Chapman for his excellent leadership. Since joining Natera in 2010, and as CEO since 2019, Steve helped grow Natera from a prenatal testing company into a global leader in precision medicine across women’s health, oncology and organ health. His impact on our business, our team and millions of patients will last for years. We’re thrilled to welcome Solomon Moshkevich as the company’s next CEO. In 15 years at Natera, Solomon has helped build nearly every part of our business and was one of the instrumental leaders in our expansion into oncology. He leads with integrity, rigor and a natural competitive spirit. I can think of no one better to lead Natera into its next chapter. And for the second consecutive time, an internal leader is stepping into the CEO role. This is a testament to the depth of this extraordinary team that we have built. Congratulations, Solomon, and thank you, Steve. natera.com/company/news/nate…
1
3
22
934
I’m grateful to Steve Chapman for his excellent leadership as Natera’s CEO, and excited to welcome Solomon Moshkevich as the company’s next CEO. 15 years at Natera, deep integrity and a true competitive spirit. The next chapter is in exceptional hands. natera.com/company/news/nate…
1
3
2
21
2,340
When we started @NateraGenetics, we believed genetics and computation could fundamentally change medicine. Nearly two decades later, we're among the top 15 on @Fortune's Future 120 list. Proud of what the team has built. We're only beginning to realize what's possible. fortune.com/ranking/future/
2
3
17
2,644
Matthew Rabinowitz retweeted
We're partnering with Aveta Biomics on a new global Phase 3 trial to help patients with head and neck cancer. Together, we're combining our Signatera™ test, which detects molecular residual disease (MRD), with Aveta's APG-157 immunotherapy. The trial will incorporate serial Signatera testing to assess MRD and treatment response throughout therapy and follow-up. This partnership has the potential to advance the field and improve care for patients with head and neck cancer, which affects nearly 950,000 people globally each year.
1
1
6
470
The goal: combine a patient's whole genome with AI trained on clinical data, and you can finally offer interventions matched to their actual biology. Lifestyle interventions, done with genuine rigor, are more powerful than most drugs we prescribe. We've built modern medicine around the easier option because changing behavior at scale is hard. Genomics and AI change that.
5
5
5
42
20,446
25 million Americans are living with a rare disease. The average diagnosis takes 4 to 7 years — not because it's untestable, but because standard diagnostic tools aren't built to find it. 1 in 17 people will be affected by a rare disease in their lifetime. Most will spend years being told nothing is wrong. Whole-genome sequencing lets the biology tell you what's there. That's the infrastructure worth building.
1
5
351
Anthropic just launched Claude Science — an AI workbench unifying 60+ scientific databases for drug discovery, plus their own programs targeting long-neglected diseases untouched by pharma. The bottleneck in drug development has always been fragmentation and time. AI is starting to fix both. cnbc.com/2026/06/30/anthropi…
1
313
Who says Israelis don't care about customer service? A cab driver a few meters from a terrorist shooting at a bus stop, helping his elderly passenger out — after she refused to leave because she hadn't reached her stop yet. youtube.com/watch?is=OgxlBoF…
1
355
Two milestones in under two months: ➡️ A landmark bladder cancer update now recommends ctDNA-MRD testing using Signatera technology ➡️ Japan's PMDA approved Signatera in colorectal cancer — the country's first ever PMDA-approved MRD test Years of clinical evidence behind each one. Proud of the @NateraGenetics team and partners making MRD-guided care a reality for patients.
It has been a big week for Natera. ✅ On Monday, new clinical practice guidelines were issued in bladder cancer, marking another important “first” for MRD-guided care and a major milestone for patients. This landmark update includes a recommendation for ctDNA-MRD testing using our Signatera™ technology in muscle-invasive bladder cancer (MIBC). ow.ly/ZG2j50ZghHC ✅ On Tuesday, Signatera received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for patients with colorectal cancer (CRC). With this approval, Signatera is the first MRD test approved by PMDA in Japan. ow.ly/G6Hj50ZghHE Coming on the heels of our recent FDA approval of Signatera™ CDx in MIBC in May, these milestones highlight the strength of our science, the value of our global partnerships, and the momentum we are building worldwide. We celebrate them together with our patients, clinicians, and the teams who made them possible. These are significant steps forward, and just the beginning!
1
1
4
910
In the early 2000s, the science to detect fetal genetic conditions already existed. What didn't exist was a clinically viable way to use it. That gap became @NateraGenetics.
1
4
266
Panorama took years to become the standard of care. Signatera spent a long time being called experimental. Neither looked inevitable in year two or five.
1
125
⁠There's a difference between building a company and changing how a field thinks. The second changes what you hire for, how you deploy capital, and what you're willing to be patient about. It's worth deciding early which one you're actually trying to do.
3
113
Matthew Rabinowitz retweeted
Signatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care Pathway Signatera ctDNA testing bridges the gap from uncertainty to actionability by answering meaningful questions at each stage of the patient’s journey. Sponsored: @NateraGenetics hubs.li/Q04kN72X0
4
3
322
For most of medicine, diagnosis is confirmation: you have a hypothesis, you run a test, you get an answer. That model works well when you know what you're looking for. Rare disease breaks that model. Most patients spend years, sometimes decades, cycling through specialists and inconclusive workups before getting a diagnosis. Not because the disease is untestable, but because nobody thought to test for it. Whole-genome sequencing inverts the model. Instead of starting with a hypothesis, you sequence the entire genome and let the biology tell you what's there. Combined with AI that can interpret millions of variants at once, you can surface conditions that would never have appeared on a differential diagnosis. That's the foundation of the rare disease test and proactive health report. The goal is finding what hypothesis-driven medicine was never going to find.
2
10
576
For most families facing a rare disease, the diagnostic journey takes 4 to 7 years. 350 million people globally. 1 in 10 individuals. Years of wrong diagnoses, unnecessary treatments, and a healthcare system that spends more investigating symptoms than sequencing the genome that could explain them. We have the technology to do better. Whole genome sequencing can identify what years of specialist visits miss. The bottleneck is not science. However, the paradigm is shifting. The question is how many families wait years for answers that could arrive in days. That number should be approaching zero.
4
1
1
6
3,177
Matthew Rabinowitz retweeted
What happens when rare disease diagnostic testing goes beyond the limits of traditional sequencing? Our new eBook highlights three real-world patient stories where advanced whole-genome analysis helped uncover diagnostic answers other labs missed. → Read  “Our Genome-First Approach in Action”to learn more: myome.com/pdfs/M-113_Our_Gen… #RareDisease #GenomeFirst
2
2
696
I've spent 20 years building diagnostics at the intersection of biology and computation. Here’s what I keep coming back to on AI in healthcare:: the models are not the problem. The problem is data silos and a lack of education. Patient data sits fragmented across institutions, and even when AI works, many clinicians aren’t trained to interpret or explain it. We’re on the edge of something transformative. But we’ll squander it if we treat infrastructure and education as afterthoughts. Went into this in depth on the Behind the Breakthroughs podcast. insideprecisionmedicine.com/…
2
3
12
1,755
When I started Natera, the idea that you could screen a fetus for chromosomal abnormalities from a blood draw in the mother's arm sounded far-fetched. The standard was amniocentesis — needle into the womb, real risk, and so invasive that many parents simply chose not to do it. We believed fetal DNA in the mother's blood could be read accurately enough to change that. It took years of signal processing, modeling, and a lot of convincing. But it worked. Panorama has now supported millions of pregnancies worldwide. That wasn't the finish line. It was proof that biology, when viewed through the right computational lens, is still largely untapped. I spoke with Maria Bartiromo on Fox Business about where this goes next.
8
7
70
248,847